Briacell Therap (NASDAQ:BCTX – Get Free Report) is anticipated to announce its results before the market opens on Monday, October 27th. Analysts expect the company to announce earnings of ($12.11) per share for the quarter.
Briacell Therap Price Performance
NASDAQ:BCTX opened at $13.79 on Friday. The business’s fifty day moving average price is $9.88 and its 200 day moving average price is $21.87. Briacell Therap has a 12 month low of $6.00 and a 12 month high of $190.50. The firm has a market capitalization of $9.38 million, a PE ratio of -0.17 and a beta of 1.21.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Briacell Therap in a research note on Friday. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Briacell Therap presently has an average rating of “Hold” and an average target price of $320.00.
About Briacell Therap
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.
Read More
- Five stocks we like better than Briacell Therap
- How Technical Indicators Can Help You Find Oversold Stocks
- Tractor Supply Stock Looks Like a Buy-and-Hold Winner
- Top Stocks Investing in 5G Technology
- 3 Stocks Well Below 52-Week Highs Poised for a Q4 Rebound
- Stock Splits, Do They Really Impact Investors?
- Big Banks Are Setting the Tone as Earnings Season Kicks Off
Receive News & Ratings for Briacell Therap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Briacell Therap and related companies with MarketBeat.com's FREE daily email newsletter.
